WINNIPEG, Manitoba, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) announces that it presented new clinical and scientific data at the Innovations in Wound Healing (“IWH”) Annual Meeting, which took place in Key West, Florida December 11-14, 2025. 

At this year’s conference, Kane Biotech shared case study data from across its wound care portfolio, underscoring the company’s commitment to addressing complex and high-burden health conditions. The link to the presentations can be found here and include:

• Clinical outcomes reported from case studies using Kane’s advanced wound gel platform, demonstrating improved healing trajectories in chronic wounds.
• Versatility over multiple sites and standards of care, featuring efficacy over different application frequencies, dressing and wound types, including highly exudative wounds.
• New findings in a Chronic Radiation-Induced Achilles Ulcer, showing how Kane’s wound gel technology supports healing in radiation-compromised tissue where conventional therapies often fail.
• Data in Hidradenitis Suppurativa (HS), illustrating the potential of revyve^®’s ability to reduce infection burden and improve outcomes in this debilitating condition.
• Market adoption insights, reflecting how Kane’s innovations are being integrated into care pathways and delivering measurable value to health systems.

FDA cleared and Health Canada approved revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray

IWH is recognized as an influential scientific forum in wound care, bringing together leading clinicians, researchers, and industry innovators accelerating the translation of breakthrough research into improved patient outcomes.

“These presentations highlight Kane Biotech’s dedication to advancing wound care innovation across a spectrum of challenging conditions,” said Dr. Robert B. Huizinga, Interim CEO of Kane Biotech. “By sharing our latest data at IWH, we continue to strengthen our role as a trusted partner in improving patient outcomes and supporting health systems with effective, science-driven solutions.”

About Kane Biotech Inc. (TSX-V: KNE)

Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results in serious clinical outcomes and significant cost. revyve^® addresses both biofilms and wound bacteria. revyve^® Antimicrobial Wound Gel and revyve^® Antimicrobial Wound Gel Spray are US FDA 510(k) cleared. revyve^® Antimicrobial Wound Gel is Health Canada approved. To learn more about revyve, visit revyvegel.com or revyvegel.ca.

Join Kane’s Distribution List & Social Media:

To stay informed on the latest developments, sign-up for the Company’s email distribution list HERE.

Follow Kane

Website: kanebiotech.com

LinkedIn: https://www.linkedin.com/company/kanebiotech/

Presentations: https://kanebiotech.com/publications-posters/ 

For more information:

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information

This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar+.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.